Abstract
In normal mammalian cells the promyelocytic leukemia protein (PML) is primarily localized in multiprotein nuclear complexes called PML nuclear bodies. However, both PML and PML nuclear bodies are disrupted in acute promyelocytic leukemia (APL). The treatment of APL patients with all-trans retinoic acid (ATRA) results in clinical remission associated with blast cell differentiation and reformation of the PML nuclear bodies. These observations imply that the structural integrity of the PML nuclear body is critically important for normal cellular functions. Indeed, PML protein is a negative growth regulator capable of causing growth arrest in the G1 phase of the cell cycle, transformation suppression, senescence and apoptosis. These PML-mediated, physiological effects can be readily demonstrated. However, a discrete biochemical and molecular model of PML function has yet to be defined. Upon first assessment of the current PML literature there appears to be a seemingly endless list of potential PML partner proteins implicating PML in a variety of regulatory mechanisms at every level of gene expression. The purpose of this review is to simplify this confusing field of research by using strict criteria to deduce which models of PML body function are well supported.
References
Melnick A, Licht JD . Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia Blood 1999 93: 3167–3215
Grimwade D, Solomon E . Characterisation of the PML/RAR alpha rearrangement associated with t(15;17) acute promyelocytic leukaemia Curr Top Microbiol Immunol 1997 220: 81–112
de Thé H, Chomienne C, Lanotte M, Degos L, Dejean A . The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus Nature 1990 347: 558–561
de Thé H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A . The PML–RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR Cell 1991 66: 675–684
Rowley JD, Golomb HM, Dougherty C . 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia Lancet 1977 1: 549–550
Kogan SC, Bishop JM . Acute promyelocytic leukemia: from treatment to genetics and back Oncogene 1999 18: 5261–5267
Daniel MT, Koken M, Romagne O, Barbey S, Bazarbachi A, Stadler M, Guillemin MC, Degos L, Chomienne C, de Thé H . PML protein expression in hematopoietic and acute promyelocytic leukemia cells Blood 1993 82: 1858–1867
Mu ZM, Chin KV, Liu JH, Lozano G, Chang KS . PML, a growth suppressor disrupted in acute promyelocytic leukemia Mol Cell Biol 1994 14: 6858–6867
Minucci S, Nervi C, Lo Coco F, Pelicci PG . Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene 2001 20: 3110–3115
Borden KLB, Campbell Dwyer EJ, Salvato MS . The promyelocytic leukemia protein PML has a pro-apoptotic activity mediated through its RING domain FEBS Lett 1997 418: 30–34
Chan JY, Li L, Fan YH, Mu ZM, Zhang WW, Chang KS . Cell-cycle regulation of DNA damage-induced expression of the suppressor gene PML Biochem Biophys Res Commun 1997 240: 640–646
Le XF, Yang P, Chang KS . Analysis of the growth and transformation suppressor domains of promyelocytic leukemia gene, PML J Biol Chem 1996 271: 130–135
Le XF, Vallian S, Mu ZM, Hung MC, Chang KS . Recombinant PML adenovirus suppresses growth and tumorigenicity of human breast cancer cells by inducing G1 cell cycle arrest and apoptosis Oncogene 1998 16: 1839–1849
Cohen N, Sharma M, Kentsis A, Perez JM, Strudwick S, Borden KL . PML RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA EMBO J 2001 20: 4547–4559
Wang ZG, Ruggero D, Ronchetti S, Zhong S, Gaboli M, Rivi R, Pandolfi PP . PML is essential for multiple apoptotic pathways Nat Genet 1998 20: 266–272
Flenghi L, Fagioli M, Tomassoni L, Pileri S, Gambacorta M, Pacini R, Grignani F, Casini T, Ferrucci PF, Martelli MF, Pelici PG, Falini B . Characterization of a new monoclonal antibody (PG-M3) directed against the aminoterminal portion of the PML gene product: immunocytochemical evidence for high expression of PML proteins on activated macrophages, endothelial cells, and epithelia Blood 1995 85: 1871–1880
Terris B, Baldin V, Dubois S, Degott C, Flejou JF, Henin D, Dejean A . PML nuclear bodies are general targets for inflammation and cell proliferation Cancer Res 1995 55: 1590–1597
Seeler JS, Dejean A . The PML nuclear bodies: actors or extras? Curr Opin Genet Dev 1999 9: 362–367
Maul GG, Negorev D, Bell P, Ishov AM . Review: properties and assembly mechanisms of ND10, PML bodies, or PODs J Struct Biol 2000 129: 278–287
Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, Gu LJ, Wang ZY . Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia Blood 1988 72: 567–572
Weis K, Rambaud S, Lavau C, Jansen J, Carvalho T, Carmo-Fonseca M, Lamond A, Dejean A . Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells Cell 1994 76: 345–356
Wang ZG, Delva L, Gaboli M, Rivi R, Giorgio M, Cordon-Cardo C, Grosveld F, Pandolfi PP . Role of PML in cell growth and the retinoic acid pathway Science 1998 279: 1547–1551
Borden KLB . Pondering the PML puzzle: possible functions for promyelocytic leukemia PML nuclear bodies Mol Cell Biol 2002 22: 5259–5269
Borden KL . RING domains: master builders of molecular scaffolds? J Mol Biol 2000 295: 1103–1112
Kentsis A, Borden K . Construction of macromolecular assemblages in eukaryotic processes and their role in human disease: linking RINGs together Curr Peptide Prot Sci 2000 1: 49–74
Goddard AD, Borrow J, Freemont PS, Solomon E . Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia Science 1991 254: 1371–1374
Borden KLB, Boddy MN, Lally J, O'Reilly NJ, Martin S, Howe K, Solomon E, Freemont PS . The solution structure of the RING finger domain from the acute promyelocytic leukaemia proto-oncoprotein PML EMBO J 1995 14: 1532–1541
Borden KLB, Lally JM, Martin SR, O'Reilly NJ, Solomon E, Freemont PS . In vivo and in vitro characterization of the B1 and B2 zinc-binding domains from the acute promyelocytic leukemia protooncoprotein PML Proc Natl Acad Sci USA 1996 93: 1601–1606
Jensen K, Shiels C, Freemont PS . PML protein isoforms and the RBCC/TRIM motif Oncogene 2001 20: 7223–7233
Negorev D, Maul GG . Cellular proteins localized at and interacting within ND10/PML nuclear bodies/PODs suggest functions of a nuclear depot Oncogene 2001 20: 7234–7242
Lai HK, Borden KL . The promyelocytic leukemia (PML) protein suppresses cyclin D1 protein production by altering the nuclear cytoplasmic distribution of cyclin D1 mRNA Oncogene 2000 19: 1623–1634
Stuurman N, de Graaf A, Floore A, Josso A, Humbel B, de Jong L, van Driel R . A monoclonal antibody recognizing nuclear matrix-associated nuclear bodies J Cell Sci 1992 101: 773–784
Everett RD, Lomonte P, Sternsdorf T, van Driel R, Orr A . Cell cycle regulation of PML modification and ND10 composition J Cell Sci 1999 112: 4581–4588
Fagioli M, Alcalay M, Pandolfi PP, Venturini L, Mencarelli A, Simeone A, Acampora D, Grignani F, Pelicci PG . Alternative splicing of PML transcripts predicts coexpression of several carboxy-terminally different protein isoforms Oncogene 1992 7: 1083–1091
Maul GG, Yu E, Ishov AM, Epstein AL . Nuclear domain 10 (ND10) associated proteins are also present in nuclear bodies and redistribute to hundreds of nuclear sites after stress J Cell Biochem 1995 59: 498–513
Everett RD . DNA viruses and viral proteins that interact with PML nuclear bodies Oncogene 2001 20: 7266–7273
Regad T, Chelbi-Alix MK . Role and fate of PML nuclear bodies in response to interferon and viral infections Oncogene 2001 20: 7274–7286
Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, Berger R . NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3) Blood 1991 77: 1080–1086
Benoit G, Roussel M, Pendino F, Segal-Bendirdjian E, Lanotte M . Orchestration of multiple arrays of signal cross-talk and combinatorial interactions for maturation and cell death: another vision of t(15;17) preleukemic blast and APL-cell maturation Oncogene 2001 20: 7161–7177
Roussel MJ, Lanotte M . Maturation sensitive and resistant t(15;17) NB4 cell lines as tools for APL physiopathology: nomenclature of cells and repertory of their known genetic alterations and phenotypes Oncogene 2001 20: 7287–7291
Duprez E, Lillehaug JR, Gaub MP, Lanotte M . Differential changes of retinoid-X-receptor (RXR alpha) and its RAR alpha and PML-RAR alpha partners induced by retinoic acid and cAMP distinguish maturation sensitive and resistant t(15;17) promyelocytic leukemia NB4 cells Oncogene 1996 12: 2443–2450
Duprez E, Lillehaug JR, Naoe T, Lanotte M . cAMP signalling is decisive for recovery of nuclear bodies (PODs) during maturation of RA-resistant t(15;17) promyelocytic leukemia NB4 cells expressing PML-RAR alpha Oncogene 1996 12: 2451–2459
Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, Jin XL, Tang W, Li XS, Xong SM, Shen ZX, Sun GL, Ma J, Zhang P, Zhang TD, Gazin C, Naoe T, Chen SJ, Wang ZY, Chen Z . In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins Blood 1996 88: 1052–1061
Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, Han ZG, Ni JH, Shi GY, Jia PM, Liu MM, He KL, Niu C, Ma J, Zhang P, Zhang TD, Paul P, Naoe T, Kitamura K, Miller W, Waxman S, Wang ZY, de The H, Chen SJ, Chen Z . Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells Blood 1997 89: 3345–3353
Zhu J, Koken MH, Quignon F, Chelbi-Alix MK, Degos L, Wang ZY, Chen Z, de Thé H . Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia Proc Natl Acad Sci USA 1997 94: 3978–3983
Wang XW, Tseng A, Ellis NA, Spillare EA, Linke SP, Robles AI, Seker H, Yang Q, Hu P, Beresten S, Bemmels NA, Garfield S, Harris CC . Functional interaction of p53 and BLM DNA helicase in apoptosis J Biol Chem 2001 276: 32948–32955
LaMorte VJ, Dyck JA, Ochs RL, Evans RM . Localization of nascent RNA and CREB binding protein with the PML-containing nuclear body Proc Natl Acad Sci USA 1998 95: 4991–4996
Borden KLB, Campbell Dwyer EJ, Carlile GW, Djavani M, Salvato MS . Two RING finger proteins, the oncoprotein PML and the arenavirus Z protein, colocalize with the nuclear fraction of the ribosomal P proteins J Virol 1998 72: 3819–3826
Tsukamoto T, Hashiguchi N, Janicki SM, Tumbar T, Belmont AS, Spector DL . Visualization of gene activity in living cells Nat Cell Biol 2000 2: 871–878
Boddy MN, Howe K, Etkin LD, Solomon E, Freemont PS . PIC 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia Oncogene 1996 13: 971–982
Duprez E, Saurin AJ, Desterro JM, Lallemand-Breitenbach V, Howe K, Boddy MN, Solomon E, de The H, Hay RT, Freemont PS . SUMO-1 modification of the acute promyelocytic leukaemia protein PML: implications for nuclear localisation J Cell Sci 1999 112: 381–393
Topcu Z, Mack DL, Hromas RA, Borden KL . The promyelocytic leukemia protein PML interacts with the proline-rich homeodomain protein PRH: a RING may link hematopoiesis and growth control Oncogene 1999 18: 7091–7100
Melchior F . SUMO – nonclassical ubiquitin Annu Rev Cell Dev Biol 2000 16: 591–626
Boddy MN, Duprez E, Borden KL, Freemont PS . Surface residue mutations of the PML RING finger domain alter the formation of nuclear matrix-associated PML bodies J Cell Sci 1997 110: 2197–2205
Ishov AM, Sotnikov AG, Negorev D, Vladimirova OV, Neff N, Kamitani T, Yeh ET, Strauss JF 3rd, Maul GG . PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1 J Cell Biol 1999 147: 221–234
Kentsis A, Dwyer EC, Perez JM, Sharma M, Chen A, Pan ZQ, Borden KL . The RING domains of the promyelocytic leukemia protein PML and the arenaviral protein Z repress translation by directly inhibiting translation initiation factor eIF4E J Mol Biol 2001 312: 609–623
Grande MA, van der Kraan I, van Steensel B, Schul W, de Thé H, van der Voort HT, de Jong L, van Driel R . PML-containing nuclear bodies: their spatial distribution in relation to other nuclear components J Cell Biochem 1996 63: 280–291
Shiels C, Islam SA, Vatcheva R, Sasieni P, Sternberg MJ, Freemont PS, Sheer D . PML bodies associate specifically with the MHC gene cluster in interphase nuclei J Cell Sci 2001 114: 3705–3716
Schul W, van Der Kraan I, Matera AG, van Driel R, de Jong L . Nuclear domains enriched in RNA 3’-processing factors associate with coiled bodies and histone genes in a cell cycle-dependent manner Mol Biol Cell 1999 10: 3815–3824
Fu XD, Maniatis T . The 35-kDa mammalian splicing factor SC35 mediates specific interactions between U1 and U2 small nuclear ribonucleoprotein particles at the 3’ splice site Proc Natl Acad Sci USA 1992 89: 1725–1729
Gall JG . Cajal bodies: the first 100 years Annu Rev Cell Dev Biol 2000 16: 273–300
Gottifredi V, Prives C . P53 and PML: new partners in tumor suppression Trends Cell Biol 2001 11: 184–187
Pearson M, Pelicci PG . PML interaction with p53 and its role in apoptosis and replicative senescence Oncogene 2001 20: 7250–7256
Li H, Chen JD . PML and the oncogenic nuclear domains in regulating transcriptional repression Curr Opin Cell Biol 2000 12: 641–644
Doucas V . The promyelocytic (PML) nuclear compartment and transcription control Biochem Pharmacol 2000 60: 1197–1201
Vallian S, Gaken JA, Trayner ID, Gingold EB, Kouzarides T, Chang KS, Farzaneh F . Transcriptional repression by the promyelocytic leukemia protein, PML Exp Cell Res 1997 237: 371–382
Alcalay M, Tomassoni L, Colombo E, Stoldt S, Grignani F, Fagioli M, Szekely L, Helin K, Pelicci PG . The promyelocytic leukemia gene product (PML) forms stable complexes with the retinoblastoma protein Mol Cell Biol 1998 18: 1084–1093
Ferbeyre G, de Stanchina E, Querido E, Baptiste N, Prives C, Lowe SW . PML is induced by oncogenic ras and promotes premature senescence Genes Dev 2000 14: 2015–2027
Boisvert FM, Kruhlak MJ, Box AK, Hendzel MJ, Bazett-Jones DP . The transcription coactivator CBP is a dynamic component of the promyelocytic leukemia nuclear body J Cell Biol 2001 152: 1099–1106
Doucas V, Tini M, Egan DA, Evans RM . Modulation of CREB binding protein function by the promyelocytic (PML) oncoprotein suggests a role for nuclear bodies in hormone signaling Proc Natl Acad Sci USA 1999 96: 2627–2632
Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S, Higashimoto Y, Appella E, Minucci S, Pandolfi PP, Pelicci PG . PML regulates p53 acetylation and premature senescence induced by oncogenic Ras Nature 2000 406: 207–210
Khan MM, Nomura T, Kim H, Kaul SC, Wadhwa R, Shinagawa T, Ichikawa-Iwata E, Zhong S, Pandolfi PP, Ishii S . Role of PML and PML-RARalpha in Mad-mediated transcriptional repression Mol Cell 2001 7: 1233–1243
Jepsen K, Hermanson O, Onami TM, Gleiberman AS, Lunyak V, McEvilly RJ, Kurokawa R, Kumar V, Liu F, Seto E, Hedrick SM, Mandel G, Glass CK, Rose DW, Rosenfeld MG . Combinatorial roles of the nuclear receptor corepressor in transcription and development Cell 2000 102: 753–763
McMahon C, Suthiphongchai T, DiRenzo J, Ewen ME . P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor Proc Natl Acad Sci USA 1999 96: 5382–5387
Guiochon-Mantel A, Savouret JF, Quignon F, Delabre K, Milgrom E, De Thé H . Effect of PML and PML-RAR on the transactivation properties and subcellular distribution of steroid hormone receptors Mol Endocrinol 1995 9: 1791–1803
Abid MR, Li Y, Anthony C, De Benedetti A . Translational regulation of ribonucleotide reductase by eukaryotic initiation factor 4E links protein synthesis to the control of DNA replication J Biol Chem 1999 274: 35991–35998
Gingras AC, Raught B, Sonenberg N . eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation Annu Rev Biochem 1999 68: 913–963
Sonenberg N, Gingras AC . The mRNA 5’ cap-binding protein eIF4E and control of cell growth Curr Opin Cell Biol 1998 10: 268–275
Lejbkowicz F, Goyer C, Darveau A, Neron S, Lemieux R, Sonenberg N . A fraction of the mRNA 5’ cap-binding protein, eukaryotic initiation factor 4E, localizes to the nucleus Proc Natl Acad Sci USA 1992 89: 9612–9616
Iborra FJ, Jackson DA, Cook PR . Coupled transcription and translation within nuclei of mammalian cells Science 2001 293: 1139–1142
Ptushkina M, von der Haar T, Vasilescu S, Frank R, Birkenhager R, McCarthy JE . Cooperative modulation by eIF4G of eIF4E-binding to the mRNA 5’ cap in yeast involves a site partially shared by p20 EMBO J 1998 17: 4798–4808
Ptushkina M, von der Haar T, Karim MM, Hughes JM, McCarthy JE . Repressor binding to a dorsal regulatory site traps human eIF4E in a high cap-affinity state EMBO J 1999 18: 4068–4075
Lang V, Zanchin NI, Lunsdorf H, Tuite M, McCarthy JE . Initiation factor eIF-4E of Saccharomyces cerevisiae. Distribution within the cell, binding to mRNA, and consequences of its overproduction J Biol Chem 1994 269: 6117–6123
Strudwick S, Borden KLB . The emerging roles of translation factor eIF4E in the nucleus Differentiation 2002 70: 10–22
Dostie J, Lejbkowicz F, Sonenberg N . Nuclear eukaryotic initiation factor 4E (eIF4E) colocalizes with splicing factors in speckles J Cell Biol 2000 148: 239–247
McCubbin WD, Edery I, Altmann M, Sonenberg N, Kay CM . Circular dichroism and fluorescence studies on protein synthesis initiation factor eIF–4E and two mutant forms from the yeast Saccharomyces cerevisiae J Biol Chem 1988 263: 17663–17671
von Der Haar T, Ball PD, McCarthy JE . Stabilization of eukaryotic initiation factor 4E binding to the mRNA 5′-cap by domains of eIF4G J Biol Chem 2000 275: 30551–30555
Cai A, Jankowska–Anyszka M, Centers A, Chlebicka L, Stepinski J, Stolarski R, Darzynkiewicz E, Rhoads RE . Quantitative assessment of mRNA cap analogues as inhibitors of in vitro translation Biochemistry 1999 38: 8538–8547
De Benedetti A, Joshi B, Graff JR, Zimmer SG . CHO cells transformed by the translation factor eIF-4E display increased c-myc expression, but require overexpression of Max for tumorigenicity Mol Cell Diff 1994 2: 347–371
Kevil CG, De Benedetti A, Payne DK, Coe LL, Laroux FS, Alexander JS . Translational regulation of vascular permeability factor by eukaryotic initiation factor 4E: implications for tumor angiogenesis Int J Cancer 1996 65: 785–790
Rosenwald IB, Lazaris-Karatzas A, Sonenberg N, Schmidt EV . Elevated levels of cyclin D1 protein in response to increased expression of eukaryotic initiation factor 4E Mol Cell Biol 1993 13: 7358–7363
Rosenwald IB, Kaspar R, Rousseau D, Gehrke L, Leboulch P, Chen JJ, Schmidt EV, Sonenberg N, London IM . Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels J Biol Chem 1995 270: 21176–21180
Shantz LM, Pegg AE . Overproduction of ornithine decarboxylase caused by relief of translational repression is associated with neoplastic transformation Cancer Res 1994 54: 2313–2316
Shantz LM, Hu RH, Pegg AE . Regulation of ornithine decarboxylase in a transformed cell line that overexpresses translation initiation factor eIF-4E Cancer Res 1996 56: 3265–3269
Polunovsky VA, Rosenwald IB, Tan AT, White J, Chiang L, Sonenberg N, Bitterman PB . Translational control of programmed cell death: eukaryotic translation initiation factor 4E blocks apoptosis in growth-factor-restricted fibroblasts with physiologically expressed or deregulated Myc Mol Cell Biol 1996 16: 6573–6581
Lazaris-Karatzas A, Montine KS, Sonenberg N . Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap Nature 1990 345: 544–547
Zimmer SG, DeBenedetti A, Graff JR . Translational control of malignancy: the mRNA cap-binding protein, eIF- 4E, as a central regulator of tumor formation, growth, invasion and metastasis Anticancer Res 2000 20: 1343–1351
Rousseau D, Kaspar R, Rosenwald I, Gehrke L, Sonenberg N . Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E Proc Natl Acad Sci USA 1996 93: 1065–1070
Haghighat A, Sonenberg N . eIF4G dramatically enhances the binding of eIF4E to the mRNA 5′-cap structure J Biol Chem 1997 272: 21677–21680
Grolleau A, Wietzerbin J, Beretta L . Defect in the regulation of 4E-BP1 and 2, two repressors of translation initiation, in the retinoid acid resistant cell lines, NB4-R1 and NB4- R2 Leukemia 2000 14: 1909–1914
Desbois C, Rousset R, Bantignies F, Jalinot P . Exclusion of Int-6 from PML nuclear bodies by binding to the HTLV-I Tax oncoprotein Science 1996 273: 951–953
Morris-Desbois C, Bochard V, Reynaud C, Jalinot P . Interaction between the Ret finger protein and the Int-6 gene product and co-localisation into nuclear bodies J Cell Sci 1999 112: 3331–3342
Gongora C, David G, Pintard L, Tissot C, Hua TD, Dejean A, Mechti N . Molecular cloning of a new interferon-induced PML nuclear body-associated protein J Biol Chem 1997 272: 19457–19463
Carlile GW, Tatton WG, Borden KL . Demonstration of a RNA-dependent nuclear interaction between the promyelocytic leukaemia protein and glyceraldehyde-3-phosphate dehydrogenase Biochem J 1998 335: 691–696
Nguyen LH, Espert L, Mechti N, Wilson DM 3rd . The human interferon- and estrogen-regulated ISG20/HEM45 gene product degrades single-stranded RNA and DNA in vitro Biochemistry 2001 40: 7174–7179
Nagy E, Rigby WF . Glyceraldehyde-3-phosphate dehydrogenase selectively binds AU-rich RNA in the NAD(+)-binding region (Rossmann fold) J Biol Chem 1995 270: 2755–2763
Singh R, Green MR . Sequence-specific binding of transfer RNA by glyceraldehyde-3-phosphate dehydrogenase Science 1993 259: 365–368
Vareli K, Frangou-Lazaridis M, van der Kraan I, Tsolas O, van Driel R . Nuclear distribution of prothymosin alpha and parathymosin: evidence that prothymosin alpha is associated with RNA synthesis processing and parathymosin with early DNA replication Exp Cell Res 2000 257: 152–161
Yeager TR, Neumann AA, Englezou A, Huschtscha LI, Noble JR, Reddel RR . Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body Cancer Res 1999 59: 4175–4179
Ford LP, Zou Y, Pongracz K, Gryaznov SM, Shay JW, Wright WE . Telomerase can inhibit the recombination-based pathway of telomere maintenance in human cells J Biol Chem 2001 276: 32198–32203
Grobelny JV, Godwin AK, Broccoli D . ALT-associated PML bodies are present in viable cells and are enriched in cells in the G(2)/M phase of the cell cycle J Cell Sci 2000 113: 4577–4585
Hachiya Y, Motonaga K, Itoh M, Masuko T, Enomoto T, Sonobe H, Takashima S . Immunohistochemical expression and pathogenesis of BLM in the human brain and visceral organs Neuropathology 2001 21: 123–128
Turley H, Wu L, Canamero M, Gatter KC, Hickson ID . The distribution and expression of the Bloom's syndrome gene product in normal and neoplastic human cells Br J Cancer 2001 85: 261–265
Yankiwski V, Marciniak RA, Guarente L, Neff NF . Nuclear structure in normal and Bloom syndrome cells Proc Natl Acad Sci USA 2000 97: 5214–5219
Gharibyan V, Youssoufian H . Localization of the Bloom syndrome helicase to punctate nuclear structures and the nuclear matrix and regulation during the cell cycle: comparison with the Werner's syndrome helicase Mol Carcinog 1999 26: 261–273
Borden KL, Campbell Dwyer EJ, Salvato MS . An arenavirus RING (zinc-binding) protein binds the oncoprotein promyelocyte leukemia protein (PML) and relocates PML nuclear bodies to the cytoplasm J Virol 1998 72: 758–766
Turelli P, Doucas V, Craig E, Mangeat B, Klages N, Evans R, Kalpana G, Trono D . Cytoplasmic recruitment of INI1 and PML on incoming HIV preintegration complexes: interference with early steps of viral replication Mol Cell 2001 7: 1245–1254
Freemont PS . RING for destruction? Curr Biol 2000 10: R84–R87
Haghighat A, Mader S, Pause A, Sonenberg N . Repression of cap-dependent translation by 4E-binding protein 1: competition with p220 for binding to eukaryotic initiation factor-4E EMBO J 1995 14: 5701–5709
Rousseau D, Gingras AC, Pause A, Sonenberg N . The eIF4E-binding proteins 1 and 2 are negative regulators of cell growth Oncogene 1996 13: 2415–2420
Yasuda S, Inoue K, Hirabayashi M, Higashiyama H, Yamamoto Y, Fuyuhiro H, Komure O, Tanaka F, Sobue G, Tsuchiya K, Hamada K, Sasaki H, Takeda K, Ichijo H, Kakizuka A . Triggering of neuronal cell death by accumulation of activated SEK1 on nuclear polyglutamine aggregations in PML bodies Genes Cells 1999 4: 743–756
Baumann CT, Ma H, Wolford R, Reyes JC, Maruvada P, Lim C, Yen PM, Stallcup MR, Hager GL . The glucocorticoid receptor interacting protein 1 (GRIP1) localizes in discrete nuclear foci that associate with ND10 bodies and are enriched in components of the 26S proteasome Mol Endocrinol 2001 15: 485–500
Lallemand-Breitenbach V, Zhu J, Puvion F, Koken M, Honore N, Doubeikovsky A, Duprez E, Pandolfi PP, Puvion E, Freemont P, de Thé H . Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation J Exp Med 2001 193: 1361–1371
Kentsis A, Gordon RE, Borden KLB . Self-assembly properties of a model RING domain Proc Natl Acad Sci USA 2002 99: 667–672
Djavani M, Rodas J, Lukashevich IS, Horejsh D, Pandolfi PP, Borden KL, Salvato MS . Role of the promyelocytic leukemia protein PML in the interferon sensitivity of lymphocytic choriomeningitis virus J Virol 2001 75: 6204–6208
Chelbi-Alix MK, Quignon F, Pelicano L, Koken MH, de Thé H . Resistance to virus infection conferred by the interferon-induced promyelocytic leukemia protein J Virol 1998 72: 1043–1051
Regad T, Saib A, Lallemand-Breitenbach V, Pandolfi PP, de Thé H, Chelbi-Alix MK . PML mediates the interferon-induced antiviral state against a complex retrovirus via its association with the viral transactivator EMBO J 2001 20: 3495–3505
Bell P, Montaner LJ, Maul GG . Accumulation and intranuclear distribution of unintegrated human immunodeficiency virus type 1 DNA J Virol 2001 75: 7683–7691
Salvato MS, Shimomaye EM . The completed sequence of lymphocytic choriomeningitis virus reveals a unique RNA structure and a gene for a zinc finger protein Virology 1989 173: 1–10
MacConnell WP, Kaplan NO . The activity of the acidic phosphoproteins from the 80 S rat liver ribosome J Biol Chem 1982 257: 5359–5366
Uchiumi T, Traut RR, Kominami R . Monoclonal antibodies against acidic phosphoproteins P0, P1, and P2 of eukaryotic ribosomes as functional probes J Biol Chem 1990 265: 89–95
Campbell Dwyer EJ, Lai H, MacDonald RC, Salvato MS, Borden KL . The lymphocytic choriomeningitis virus RING protein Z associates with eukaryotic initiation factor 4E and selectively represses translation in a RING-dependent manner J Virol 2000 74: 3293–3300
Maul GG, Guldner HH, Spivack JG . Modification of discrete nuclear domains induced by herpes simplex virus type 1 immediate early gene 1 product (ICP0) J Gen Virol 1993 74: 2679–2690
Chelbi-Alix MK, de Thé H . Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML and Sp100 proteins Oncogene 1999 18: 935–941
Everett RD, Earnshaw WC, Findlay J, Lomonte P . Specific destruction of kinetochore protein CENP-C and disruption of cell division by herpes simplex virus immediate-early protein Vmw110 Embo J 1999 18: 1526–1538
Parkinson J, Everett RD . Alphaherpesvirus proteins related to herpes simplex virus type 1 ICP0 affect cellular structures and proteins J Viroll 2000 74: 10006–10017
Everett RD . ICP0 induces the accumulation of colocalizing conjugated ubiquitin J Viroll 2000 74: 9994–10005
Hodges M, Tissot C, Howe K, Grimwade D, Freemont PS . Structure, organization, and dynamics of promyelocytic leukemia protein nuclear bodies Am J Hum Genet 1998 63: 297–304
De Benedetti A, Harris AL . eIF4E expression in tumors: its possible role in progression of malignancies Int J Biochem Cell Biol 1999 31: 59–72
Wang S, Rosenwald IB, Hutzler MJ, Pihan GA, Savas L, Chen JJ, Woda BA . Expression of the eukaryotic translation initiation factors 4E and 2alpha in non-Hodgkin's lymphomas Am J Pathol 1999 155: 247–255
Berkel HJ, Turbat-Herrera EA, Shi R, de Benedetti A . Expression of the translation initiation factor eIF4E in the polyp-cancer sequence in the colon Cancer Epidemiol Biomarkers Prev 2001 10: 663–666
DeFatta RJ, Turbat-Herrera EA, Li BD, Anderson W, De Benedetti A . Elevated expression of eIF4E in confined early breast cancer lesions: possible role of hypoxia Int J Cancer 1999 80: 516–522
Franklin S, Pho T, Abreo FW, Nassar R, De Benedetti A, Stucker FJ, Nathan CA . Detection of the proto-oncogene eIF4E in larynx and hypopharynx cancers Arch Otolaryngol Head Neck Surg 1999 125: 177–182
Li BD, McDonald JC, Nassar R, De Benedetti A . Clinical outcome in stage I to III breast carcinoma and eIF4E overexpression Ann Surg 1998 227: 756–761 discussion 761–763
Kogan SC, Hong SH, Shultz DB, Privalsky ML, Bishop JM . Leukemia initiated by PMLRARalpha: the PML domain plays a critical role while retinoic acid-mediated transactivation is dispensable Blood 2000 95: 1541–1550
Brown D, Kogan S, Lagasse E, Weissman I, Alcalay M, Pelicci PG, Atwater S, Bishop JM . A PMLRARalpha transgene initiates murine acute promyelocytic leukemia Proc Natl Acad Sci USA 1997 94: 2551–2556
Bargonetti J, Manfredi JJ . Multiple roles of the tumor suppressor p53 Curr Opin Oncol 2002 14: 86–91
Rubin DM, Coux O, Wefes I, Hengartner C, Young RA, Goldberg AL, Finley D . Identification of the gal4 suppressor Sug1 as a subunit of the yeast 26S proteasome Nature 1996 379: 655–657
Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A . Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours Nature 1992 356: 215–221
Topisirovic I, Capili AD, Borden KLB . Interferon γ and cadmium treatments modulate eIF4E dependent mRNA transport of cyclin D1 in a PML dependent manner Mol Cell Biol 2002 (in press)
Minucci S, Maccarana M, Cioci M, De Luca P, Gelmetti V, Segalla S, Di Croce L, Giavara S, Matteucci C, Gobbi A, Bianchini A, Colombo E, Schiavoni I, Badaracco G, Hu X, Lazar M, Pelicci PG . Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation Mol Cell Biol 2000 5: 811–820
Acknowledgements
SS is a fellow of the Samuel Waxman Cancer Research Foundation. KLBB is a scholar of the Leukemia and Lymphoma Society. Financial support was provided by NIH grants (CA 80728 and CA 88991).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Strudwick, S., Borden, K. Finding a role for PML in APL pathogenesis: a critical assessment of potential PML activities. Leukemia 16, 1906–1917 (2002). https://doi.org/10.1038/sj.leu.2402724
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402724
- Springer Nature Limited
Keywords
This article is cited by
-
PML4 induces differentiation by Myc destabilization
Oncogene (2007)
-
The promyelocytic leukemia protein stimulates SUMO conjugation in yeast
Oncogene (2006)
-
Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate
Leukemia (2003)
-
Spotlight on acute promyelocytic leukemia: controversies and challenges
Leukemia (2002)